PLOS ONE

CORRECTION

# Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

**Marius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, Lingkang Huang, Jonathan Juco, Veronique Hofman, Paul Hofman**

Fig 1 is incorrect. The authors have provided a corrected version here.





**Citation:** Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, et al. (2017) Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE 12 (10): e0186537. https://doi.org/10.1371/journal.pone.0186537

**Published:** October 13, 2017




**Fig 1. Optimised protocols for PD-L1 IHC assays using the 22C3 antibody concentrate on the Dako ASL48 and VENTANA BenchMark ULTRA platforms.** PD-L1, programmed death ligand 1; IHC, immunohistochemistry; ASL48, Autostainer Link 48; DAB, 3,3'-diaminobenzidine tetrahydrochloride.

https://doi.org/10.1371/journal.pone.0186537.g001

## Reference

1. Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, et al. (2017) Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE 12(8): e0183023. https://doi.org/10.1371/journal.pone.0183023 PMID: 28797130